Vitamin K-dependent proteins regulate blood coagulation as well as bone growth and calcification. Here, we have compared the effects of oral anticoagulants on circulating vitamin K-dependent proteins and on markers for calcium and bone metabolism. Patients with a clinical indication for antithrombotic therapy were randomized into three groups and treated with either aspirin, regular-intensity anticoagulation [target international normalized ratio (INR) values: 2.5–3.5] or low-intensity anticoagulation (target INR values: 1.1–1.6). At the start and after 1 year of treatment, various biochemical markers were assessed. Both the circulating levels and the degree of carboxylation of the various γ-carboxyglutamate (Gla)-containing proteins were affected differently by oral anticoagulant treatment. Circulating osteocalcin was more sensitive to poor vitamin K status than other Gla proteins. From the fact that – except for osteocalcin – neither markers for osteoblast nor osteoclast function were affected by oral anticoagulant treatment, we conclude that bone turnover remained unaltered, which is indicative of an unchanged rate of bone loss. Whether the long-term production of undercarboxylated bone Gla proteins may have a negative effect on the quality of bone (e.g. bone strength) cannot be concluded from this study.

Keywords:
Vitamin K, Coumarin, Thromboembolism, Side effects, Osteocalcin
1.
Vermeer C: Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J 1990;266:625–636.
2.
Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G: Increased bone formation in osteocalcin-deficient mice. Nature 1996;382:448–452.
3.
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix Gla protein. Nature 1997;386:78–81.
4.
Hall JG, Pauli RM, Wilson KM: Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122–140.
5.
Knapen MHJ, Hamulyák K, Vermeer C: The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 1989;111:1001–1005.
6.
Orimo H, Fujita T, Onomura T, Inoue T, Kushida K, Shiraki M: Clinical evaluation of Ea-0167 (Menatetrenone) in the treatment of osteoporosis. Clin Eval (Tokyo) 1992;20:45–100.
7.
Sato Y, Honda Y, Kunoh H, Oizumi K: Long-term oral anticoagulation reduces bone mass in patients with previous hemispheric infarction and nonrheumatic atrial fibrillation. Stroke 1997;28:2390–2394.
8.
Rosen HN, Maitland LA, Suttie JW, Manning WJ, Glynn RJ, Greenspan SL: Vitamin K and maintenance of skeletal integrity in adults. Am J Med 1993;94:62–68.
9.
Langenberg M, Hellemons BSP, van Ree JW, Vermeer F, Lodder J, Schouten HJA, Knottnerus JA: Atrial fibrillation in elderly patients: Prevalence and comorbidity in general practice. BMJ 1996;313:1534.
10.
Behr W, Barnert J: Quantification of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: A simplified method and its clinical plausibility. Clin Chem 1986;32:1960–1966.
11.
Vermeer C, Soute BAM, Hemker HC: A new method for the preparation of artificial factor II reagents from normal human and bovine plasma. Thromb Res 1977;10:495–507.
12.
Jie K-SG, Bots ML, Vermeer C, Witteman JCM, Grobbee DE: Vitamin K status and bone mass in women with and without aortic atherosclerosis: A population-based study. Calcif Tissue Int 1996;59:352–356.
13.
Szulc P, Chapuy M-C, Meunier PJ, Delmas PD: Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up study. Bone 1996;18:487–488.
14.
Wu W, Bancroft JD, Suttie JW: Differential effects of warfarin on the intracellular processing of vitamin K-dependent proteins. Thromb Haemost 1996;76:46–52.
15.
Chu K, Wu S-M, Stanley T, Stafford DW, High KA: A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. J Clin Invest 1996;98:1619–1625.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.